These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 17940007)

  • 1. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits.
    DiFiglia M; Sena-Esteves M; Chase K; Sapp E; Pfister E; Sass M; Yoder J; Reeves P; Pandey RK; Rajeev KG; Manoharan M; Sah DW; Zamore PD; Aronin N
    Proc Natl Acad Sci U S A; 2007 Oct; 104(43):17204-9. PubMed ID: 17940007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease.
    Stanek LM; Sardi SP; Mastis B; Richards AR; Treleaven CM; Taksir T; Misra K; Cheng SH; Shihabuddin LS
    Hum Gene Ther; 2014 May; 25(5):461-74. PubMed ID: 24484067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mRNA Nuclear Clustering Leads to a Difference in Mutant Huntingtin mRNA and Protein Silencing by siRNAs
    Allen S; O'Reilly D; Miller R; Sapp E; Summers A; Paquette J; Echeverria Moreno D; Bramato B; McHugh N; Yamada K; Aronin N; DiFiglia M; Khvorova A
    Nucleic Acid Ther; 2024 Aug; 34(4):164-172. PubMed ID: 39023561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA.
    Wang YL; Liu W; Wada E; Murata M; Wada K; Kanazawa I
    Neurosci Res; 2005 Nov; 53(3):241-9. PubMed ID: 16095740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Msh2 acts in medium-spiny striatal neurons as an enhancer of CAG instability and mutant huntingtin phenotypes in Huntington's disease knock-in mice.
    Kovalenko M; Dragileva E; St Claire J; Gillis T; Guide JR; New J; Dong H; Kucherlapati R; Kucherlapati MH; Ehrlich ME; Lee JM; Wheeler VC
    PLoS One; 2012; 7(9):e44273. PubMed ID: 22970194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allele-specific silencing of mutant huntingtin in rodent brain and human stem cells.
    Drouet V; Ruiz M; Zala D; Feyeux M; Auregan G; Cambon K; Troquier L; Carpentier J; Aubert S; Merienne N; Bourgois-Rocha F; Hassig R; Rey M; Dufour N; Saudou F; Perrier AL; Hantraye P; Déglon N
    PLoS One; 2014; 9(6):e99341. PubMed ID: 24926995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo.
    Huang B; Schiefer J; Sass C; Landwehrmeyer GB; Kosinski CM; Kochanek S
    Hum Gene Ther; 2007 Apr; 18(4):303-11. PubMed ID: 17472569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
    Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
    Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of a rat model of Huntington's disease based on targeted expression of mutant huntingtin in the forebrain using adeno-associated viral vectors.
    Gabery S; Sajjad MU; Hult S; Soylu R; Kirik D; Petersén Å
    Eur J Neurosci; 2012 Sep; 36(6):2789-800. PubMed ID: 22731249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease.
    Van Raamsdonk JM; Pearson J; Murphy Z; Hayden MR; Leavitt BR
    BMC Neurosci; 2006 Dec; 7():80. PubMed ID: 17147801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Artificial miRNAs Reduce Human Mutant Huntingtin Throughout the Striatum in a Transgenic Sheep Model of Huntington's Disease.
    Pfister EL; DiNardo N; Mondo E; Borel F; Conroy F; Fraser C; Gernoux G; Han X; Hu D; Johnson E; Kennington L; Liu P; Reid SJ; Sapp E; Vodicka P; Kuchel T; Morton AJ; Howland D; Moser R; Sena-Esteves M; Gao G; Mueller C; DiFiglia M; Aronin N
    Hum Gene Ther; 2018 Jun; 29(6):663-673. PubMed ID: 29207890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular Analysis of Silencing the Huntington's Disease Gene Using AAV9 Mediated Delivery of Artificial Micro RNA into the Striatum of Q140/Q140 Mice.
    Keeler AM; Sapp E; Chase K; Sottosanti E; Danielson E; Pfister E; Stoica L; DiFiglia M; Aronin N; Sena-Esteves M
    J Huntingtons Dis; 2016 Oct; 5(3):239-248. PubMed ID: 27689620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.
    Tanaka Y; Igarashi S; Nakamura M; Gafni J; Torcassi C; Schilling G; Crippen D; Wood JD; Sawa A; Jenkins NA; Copeland NG; Borchelt DR; Ross CA; Ellerby LM
    Neurobiol Dis; 2006 Feb; 21(2):381-91. PubMed ID: 16150600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.
    Boudreau RL; McBride JL; Martins I; Shen S; Xing Y; Carter BJ; Davidson BL
    Mol Ther; 2009 Jun; 17(6):1053-63. PubMed ID: 19240687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease.
    Franich NR; Fitzsimons HL; Fong DM; Klugmann M; During MJ; Young D
    Mol Ther; 2008 May; 16(5):947-56. PubMed ID: 18388917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice.
    Rodriguez-Lebron E; Denovan-Wright EM; Nash K; Lewin AS; Mandel RJ
    Mol Ther; 2005 Oct; 12(4):618-33. PubMed ID: 16019264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
    Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
    J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deletion of the huntingtin polyglutamine stretch enhances neuronal autophagy and longevity in mice.
    Zheng S; Clabough EB; Sarkar S; Futter M; Rubinsztein DC; Zeitlin SO
    PLoS Genet; 2010 Feb; 6(2):e1000838. PubMed ID: 20140187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington's disease.
    Boussicault L; Alves S; Lamazière A; Planques A; Heck N; Moumné L; Despres G; Bolte S; Hu A; Pagès C; Galvan L; Piguet F; Aubourg P; Cartier N; Caboche J; Betuing S
    Brain; 2016 Mar; 139(Pt 3):953-70. PubMed ID: 26912634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained effects of nonallele-specific Huntingtin silencing.
    Drouet V; Perrin V; Hassig R; Dufour N; Auregan G; Alves S; Bonvento G; Brouillet E; Luthi-Carter R; Hantraye P; Déglon N
    Ann Neurol; 2009 Mar; 65(3):276-85. PubMed ID: 19334076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.